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Background: Neuromyelitis optica (NMO) includes transverse myelitis, optic neuritis and brain lesions.
Recent studies have indicated that the brainstem is an important site of attack in NMO. Longitudinally extensive
transverse myelitis (LETM) is an important component of the clinical diagnosis of NMO. The frequency of brainstem
and LETM lesions, changes over time of LETM and the clinical consequences in the course of NMO have only been
sparsely studied.
Methods: The study was a population-based retrospective case series with clinical and magnetic resonance
imaging (MRI) follow-up of 35 patients with definite NMO and a relapsing-remitting course.
Results: Brainstem lesions were observed in 25 patients, 18 in medulla oblongata (11 in area postrema). Lesions in
the pons, mesencephalon and diencephalon occurred in 10, 7 and 7 patients, respectively. Lesions were
symptomatic in medulla oblongata and pons, asymptomatic in mesencephalon and diencephalon. Brainstem
lesions were observed significantly more often in anti-aquaporin-4 (AQP-4) antibody positive than in seronegative
patients (p < 0.002).
LETM was demonstrated by MRI of the spinal cord in 30/36 patients, 23/30 of whom had follow-up MRI of the
spinal cord. Recurrent LETM was observed in five patients. In nine patients the LETM changed into multiple lesions
during remission or treatment. Spinal cord atrophy was observed in 12/23 (52%) patients, correlating to Expanded
Disability Status Scale (r = 0.88, p < 0.001).
Conclusions: NMO patients had frequent occurrence of brainstem lesions and LETM. Brainstem lesions were
associated with anti-AQP4 antibody positivity. LETM lesions differentiated over time and the outcome included
relapses, fragmentation and atrophy. Correlation was observed between spinal cord atrophy and neurological
disability.
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Neuromyelitis optica (NMO) is characterized by inflam-
mation of the optic nerve and the spinal cord [1]. Disco-
very of serum immunoglobulin G autoantibody towards
the water channel aquaporin 4 (AQP4) led to the re-
cognition of NMO patients with clinical signs and/or
lesions in the CNS outside of the optic nerve and
spinal cord [2-4].
NMO is diagnosed by the demonstration of a combi-
nation of clinical manifestations, radiological abnor-
malities and serological demonstration of anti-AQP4
antibodies [4]. The diagnosis of definite NMO may be
made solely on clinical and magnetic resonance imaging
(MRI)-based analysis in a high proportion of cases
[2,4,5]. However, the demonstration of anti-AQP4 anti-
bodies/NMO-IgG is obligatory in the diagnosis of the
NMO spectrum disease, which includes patients with
clinical signs and/or MRI lesions in the CNS outside of
the optic nerve and spinal cord [4]. Thus, NMO may
include more complex and heterogeneous clinical pre-
sentations with brain syndromes occasionally leading to
considerable diagnostic difficulty. A number of studies
have shown brain abnormalities as detected by MRI in
60-71% of NMO patients [3,6-9]. The brain lesions are
often localized at sites of high AQP4 expression [10].
The heterogeneous clinical presentations in such NMO
patients include brain syndromes such as endocrino-
pathies [11], posterior reversible encephalopathy syn-
drome [12] and brainstem syndrome. The brainstem
syndrome may lead to respiratory failure [4] or persis-
tent intractable hiccups and nausea [13,14].
Peripheral blood is a likely source for antibody in the
CNS [15], but it is not known how anti-AQP4 antibodies
reach the CNS [16]. The clinical occurrence of brain-
stem lesions including area postrema may be related to
the areas with high density of AQP4 expression and lack
of blood brain barrier [17,18] and it has been sug-
gested that area postrema is a portal of entry to the
CNS for anti-AQP4 antibodies [13,18]. However, more
detailed studies are required to obtain evidence for
the frequency and clinical consequences of brainstem
lesions.
In the spinal cord the longitudinally extensive transverse
myelitis (LETM) lesion, regarded as typical for NMO, is
characterized by involvement of three or more vertebral
segments [4]. The changes over time of LETMs and their
long term clinical consequences have only been sparsely
reported.
The aims of the present study were to estimate the
frequency of abnormalities of the brainstem and the spinal
cord lesions during the course of NMO and to obtain
information about dynamic changes of spinal cord lesions
during long-term follow-up. Symptoms and clinical fin-
dings were reported.Methods
Study design
A clinical database for NMO patients diagnosed in the
time period 1998-2008 in the Region of Southern
Denmark was established as part of a population-based
study reported in detail elsewhere [2]. The study was a
population-based retrospective case series with longitu-
dinal prospective follow-up as described in detail previ-
ously [2]. NMO patients were diagnosed according to
the Wingerchuk 2006 criteria [4]. Information was
obtained by means of review of medical records, a ques-
tionnaire, a clinical examination, re-evaluation of previ-
ous MRIs of CNS, study examination of supplementary
MRIs and serum anti-AQP4-antibody determinations.Clinical material
A total of 36 patients with definite NMO were identified in
the database and included in the present study. All patients
were Caucasians except one. All had a relapsing-remitting
course except one, who had a monophasic course. The
female: male ratio was 2.8: 1 and mean age at onset was
35.6 years (15–64 years). Disability was retrieved from the
medical records where it had been measured by Expanded
Disability Status Scale (EDSS) [19].Radiographic material
Since the study was retrospective, several types of MRI
scanners were used with a variety of imaging techniques.
T2-weighted (T2W), T1-weighted (T1W) images with
or without gadolinium (Gd), diffusion-weighted imaging
(DWI) and fluid-attenuated inversion recovery (FLAIR)
sequences were analysed in MRIs of brain. T2W, T1W
with or without gadolinium and short tau inversion
recovery (STIR) sequences were analysed in spinal cord
imaging. Supplementary MRIs of CNS were performed on
a 1.5 Tesla scanner (GE, Paris, France). The typology and
characteristics of brainstem lesions were described in de-
tail based on a combination of information from the axial
and/or sagittal T2-weighted, the T1-weighted + gadoli-
nium and FLAIR MRIs. The lesions (≥ 3 mm) were de-
scribed by location (infratentorial, medulla oblongata, area
postrema, pons, mesencephalon, diencephalon). Spinal
cord MRI was either reported as normal, as abnormal with
a shorter lesion not suggestive of NMO, or as LETM (cord
lesion extending 3 or more vertebral segments). LETMs
had a high signal on T2-weighted images and if obtained
during acute episodes of myelitis showed hypointensity on
T1-weighted images. Spinal cord atrophy was defined as a
sagittal diameter of ≤ 4 mm on T1 weighted sequences
[20] and was classified with regard to extent of atrophy, 0
denotes no atrophy, focal denotes atrophy of limited ex-
tent, and general atrophy denotes changes involving both
cervical and thoracic spinal cord. The neuroradiologist
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gations. MRI data were reported in a written.
Anti-AQP4 antibodies
IgG AQP4 antibodies were measured with a recombi-
nant immuno-fluorescence assay using HEK293 cells
transfected with recombinant human full-length AQP4
gene [21,22]. Materials were obtained from Euroimmun
(Lubeck, Germany). Patient sera were screened at a 1:10
dilution. Analyses were done in an accredited labora-
tory at the Department of Clinical Immunology, Odense
University Hospital.
Statistical analysis
Spinal cord atrophy was classified as no atrophy, focal
atrophy or general atrophy and EDSS was divided in
three groups (categorical variables with 3 categories).
Intergroup differences were analyzed using polychoric
correlation and Fisher’s exact test on the corresponding
3x3 tables. Statistical analyses were performed using
Stata 11 (StataCorp LP, College Station, Texas, USA).
The limit of significance was chosen as p < 0.05.
Protocol approvals, registrations, and patient consent
The study which formed the basis for the database was ap-
proved by The Committee on Biomedical Research Ethics
for the Region of Southern Denmark (Ref. no. S-20080142)
and The Danish Data Protection Agency (Ref. no. 2008-
41-2826). All patients provided written informed consent.
Results
Radiological and clinical characteristics of brainstem lesions
The frequency of brainstem abnormalities was estimated
for 31/35 NMO patients who had available follow-up
MRI analysis. Lesions were observed in the brainstem atTable 1 Characteristics of brainstems lesions in NMO patients
Clinical manifestations Anti-AQP4 antibod
Number of pati
MRI of brain At disease onset
Normal 8
Non-specific changes 10
MS-like changes* 0
Topological distribution of Brainstem lesions** F/m Sym Asym
Medulla oblongata 10/2 12 0
Area postrema 6/2 8 0
Pons 6/1 7 0
Mesencephalon 2/1 0 3
Hypothalamic and thalamic 5/0 0 5
* = meeting the Barkhof criteria for dissemination in space used in the McDonald c
a total of 25/31 NMO patients.least once in 25/31 (81%) patients, 18 (72%) of whom
were seropositive (Table 1). MRI-lesions in the medulla
oblongata were detected in 18 (58%) patients. Of those
patients 11 had lesions in the area postrema (Figure 1).
Lesions in the pons occurred in 10/25 (40%) and in the
mesencephalon in 7/25 (28%) patients. Lastly, hypothal-
amic and thalamic lesions were observed in 7/25 (28%).
A significantly higher frequency of brainstem lesions
were observed in anti-AQP-4 antibody positive (18/18)
than in seronegative (7/13) patients (p < 0.002).
Based on information from questionnaires and patient
files, lesions were uniformly symptomatic in medulla
oblongata and pons. Patients with lesions in mesence-
phalon and diencephalon did not show apparent symp-
toms. The symptoms were typically polysymptomatic
and reversible. The clinical presentation mainly reflected
dysfunction of the medulla oblongata and included
symptoms such as respiratory failure in 6/31 (19%), 5
seropositive, intractable hiccups and nausea in 9/31
(29%), 8 seropositive, vomiting and nausea in 13/31
(42%), 9 seropositive and bradycardia, blood pressure
fluctuations in 5/31 (16%), 4 seropositive. Other clinical
signs in the patients with brainstem lesions were: vertigo
23 (74%), 13 seropositive, diplopia 6 (19%), 3 seroposi-
tive, facial weakness 2 (6%), 2 seropositive, nystagmus 2
(6%), 1 seropositive and ataxia 4(13%), 3 seropositive.
Overall, anti-AQP4-antibody determinations were posi-
tive in 72% of the patients.
Radiological and clinical characteristics of spinal cord lesions
Spinal cord MRI demonstrated LETM in 30/36 patients.
Cervical LETM occurred in 21/30 (70%), 8 (27%)
reaching into the brainstem. Thoracic TM occurred in
9/30 (30%) cases. Cord lesions involving both cervical
and thoracic cord was observed in 13/30 (43%).(31)
ies positive Anti-AQP4 antibodies negative
ents = 18 Number of patients = 13
At follow-up At disease onset At follow-up
2 6 1
8 8 6
8 0 7
EDDS F/m Sym Asym EDDS
2-4 5-7 8-9 2-4 5-7 8-9
4 4 4 4/2 6 0 2 4 0
3 3 2 1/2 3 0 0 1 2
2 2 3 2/1 3 0 0 1 2
0 2 1 3/1 0 2 0 3 1
1 2 2 1/1 0 0 1 1 0
riteria as described previously [2]. ** = Lesions were observed in the brainstem
Figure 1 Typical brain MRI lesions in neuromyelitis optica. Representative MRI of six NMO patients; Upper row: FLAIR; lower row: T2W, A.
Lesions in hypothalamic region, B. Lesions in periaqueductal matter in mesencephalon, C and D. Lesions in medulla oblongata, E and F. Lesions
in area postrema of the medulla oblongata.
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tetraplegia or paraplegia, a well-defined symmetric sen-
sory affection and different degrees of pain and paroxys-
mal tonic spasms of the trunk and the extremities. The
cervical lesions tended to be accompanied by sphincter
dysfunction to a higher degree than the thoracic lesions.
Out of 30 patients 23 had follow-up MRIs of spinal
cord, 17/23 (74%) were anti-AQP4 seropositive (Table 2).
Recurrent LETM was observed in 5/23 patients (22%),Table 2 Clinical characterisation and MRI follow-up of NMO p
(LETM) (n = 23)
Clinical
manifestations
F/M Anti-AQP4 antibodies posi
Number of patients = 17
Duration of disease EDSS
2-4 y 5-10 y 2-4 5
MRI of the spinal cord
Single LETM 14/3 17 10 7 5
Brainstem involvement 7/0 7 5 2 0
Relapsing LETM 4/0 4 3 1 0
Multiple shorter TM 5/1 6 4 2 0
Normal SC 2/1 3 3 0 3
Focal atrophy of SC 0 0 0 0 0
General atrophy of SC 4/1 5 4 1 0
F/M = Female/male, EDSS = Expanded Disability Status Scale, LETM = longitudinallyall female. Following treatment with high-dose steroids,
LETMs changed into multiple shorter plaques in 9/23
(39%) patients. Primary MRI was performed within two
days of symptoms followed by treatment with high-dose
steroids. The time interval from steroid treatment to the
control MRI was three to six months (Figures 2 and 3).
Evaluation of spinal cord atrophy was determined in
23/30 NMO patients who had follow-up MRIs over a
period of time. Focal spinal cord atrophy at the site ofatients with longitudinally extensive transverse myelitis
tive F/M Anti-AQP4 antibodies negative
Number of patients = 6
Score Duration of disease EDSS Score
-7 8-9 2-4 y 5-10 y 2-4 5-7 8-9
5 7 3/3 6 3 3 1 4 1
1 6 1/0 1 0 1 0 0 1
1 3 1/0 1 1 0 0 1 0
1 5 1/2 3 2 1 0 2 1
0 0 0 0 0 0 0 0 0
0 0 3/2 5 5 0 0 5 0
0 5 1/1 2 1 1 0 0 2
extensive transverse myelitis, SC = Spinal cord, TM = Transverse myelitis.
Figure 2 Characteristics of follow-up MRI of longitudinally
extensive transverse myelitis (LETM) in 23 NMO patients.
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2-4 year duration of disease and with an EDSS score of 5-7.
General spinal cord atrophy was observed in 7/23 (30%)
patients after 2-4 years duration of disease in two and after
5-10 years in five with an EDDS score of 7-9. A strong
correlation was observed (r = 0.88) between the occurrence
of spinal cord atrophy and disability as analyzed by
the polychoric correlation and the Fisher’s exact test
(p < 0.001). Normal appearance of the spinal cord was only
observed in 3/23 (13%) patients and myelitis lesions shorter
than LETM were found in 7/23 (30%) patients, afterFigure 3 Modifications of longitudinally extensive transverse myelitis
anti-AQP4 antibody positive patient with NMO A: primary LETM in the upp
shown) B: Fragmentation (small arrows) of the earlier LETM following treatm
cervical cord 3 months later.2-4 year duration of disease with an EDSS score of 2-4
(Figures 2 and 4).
Discussion
In the present study of 35 cases from a population-based
NMO cohort a high frequency of brainstem lesions and
corresponding clinical signs was observed. Brainstem
abnormalities were detected by MRI in 81%, the majority
observed in the medulla oblongata (58%) including 35%
with lesions in the area postrema. Brainstem lesions
were observed more often in AQP4 antibody positive
than in seronegative patients (p < 0.002). There was a
high degree of agreement between MRI and clinical
presentation of brainstem lesions. The study supports
the notion that the brainstem, in particular medulla
oblongata and area postrema, are important points of
attack in NMO [13,18]. These data are in accordance
with a multicenter study in Caucasians that found that
seropositive patients were predominantly female and
had a more severe clinical course [7]. Furthermore, a
study from China observed that lesions in the brainstem
occurred in a significant proportion of patients [23].
A relative lack of intrathecal synthesis of anti-AQP4
antibodies/NMO-IgG [24,25] and perivascular pathology
in NMO suggests entry of antibody from blood vessels
to CNS [15]. The BBB restricts entry of serum proteins
into the CNS [26]. However, the BBB is not absolute,
notably in circumventricular areas including the area(LETM). Spinal cord MRI: sagittal T2WI of spinal cord from an
er thoracic cord (arrow) extending from Th1 – 6 (lower limit not
ent with high-dose steroids and a new LETM (circle) in the lower
Figure 4 Longitudinally extensive transverse myelitis (LETM) and atrophy of spinal cord following LETM. Spinal cord MRI: sagittal T2WI
(A and B) and T1WI (C) from three anti-AQP4- antibody positive NMO patients. A. MRI showing cervical spinal cord LETM with swelling. B. MRI
showing LETM of cervical and upper 2/3 thoracic spinal cord. C. Severe atrophy of spinal cord as a consequence of recurrent LETM after 6 years
duration of disease.
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area postrema is a portal for entry of circulating IgG to
the CNS in NMO [13,14,18,27].
LETM lesions are regarded as typical for NMO and
may be important non-serological markers for NMO
[28]. We observed that LETM tended to occur with high
frequency during the course of NMO. Furthermore
LETM lesions in a considerable proportion of patients
changed into multiple fragments during remission or
following treatment with high-dose steroids. The present
study and other studies [28,29] suggest that evaluation
of spinal cord MRI should consider the interval between
the acute myelitis attack and the MRI scan. A previous
LETM due to NMO may be considered as a differential
diagnosis in patients with closely located multiple lesions
and atrophy on MRI of the spinal cord. Such an inter-
pretation may help in the understanding of the neuro-
logical disability in NMO patients as well as assist in the
differentiation of NMO from multiple sclerosis (MS).
It has previously been observed in MS patients that
spinal cord atrophy correlates well with concurrent mea-
sures of disability [30]. In this study of NMO a strong
correlation was observed between spinal cord atrophy
and clinical disability as measured by neurological as-
sessment (EDSS). Similar findings of spinal cord atrophy
were reported in a study of 20 Afro-Caribbean NMO-
patients [20].
Primary strengths of this study were the population-
based patient material which originated from a cohort
with a high representativity, and the relatively uniformlong-term clinical and MRI follow-up. Furthermore, the
radiological and the clinical evaluations were performed
in a blinded fashion so one specialist did not have the
information of the other, in order to minimize bias in
the interpretation.
A limitation of this study was the use of different types
of MRI scanners with a variety of imaging techniques and
a variety of intervals from the onset of clinical mani-
festations to MRI examination. Also, the clinical evalu-
ation including the EDSS was done by different clinicians
at a variety of intervals. However, these limitations reflect
the clinical setting of the study as a consequence of its
retrospective nature.Conclusions
In conclusion the present population-based study demon-
strates the frequent occurrence of brainstem lesions and
LETMs in NMO patients during the course of NMO. All
seropositive patients had brainstem lesions. Modifications
of LETMs and brainstem lesions and their relation to the
clinical outcome were observed in the course of NMO.
The MRI data indicate that LETM lesions differentiated
over time to relapses, multiple shorter lesions and atrophy.
Consequently, the timing of MRI of the spinal cord may
be important for the demonstration of LETM. Large, pre-
ferably prospective patient cohort studies are required to
obtain more solid evidence on dynamic changes of lesions
by MRI and the relationship to clinical presentation as
well as to anti-AQP4-antibody levels.
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